Tomas Kalincik, Sifat Sharmin, Izanne Roos, Jennifer Massey, Ian Sutton, Barbara Withers, Mark S Freedman, Harold Atkins, Eva Krasulova, Eva Kubala Havrdova, Marek Trneny, Tomas Kozak, Joachim Burman, Richard Macdonell, Øivind Torkildsen, Lars Bø, Anne Kristine Lehmann, Basil Sharrack, John Snowden
BACKGROUND: Natalizumab was not shown to modify disability in progressive multiple sclerosis (MS). This matched observational study compared the effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) with natalizumab in progressive MS. METHODS: Patients with primary/secondary progressive MS from seven AHSCT MS centres and the MSBase registry, treated with AHSCT or natalizumab, were matched on a propensity score derived from sex, age, Expanded Disability Status Scale (EDSS), number of relapses 12/24 months before baseline, time from MS onset, the most effective prior therapy and country...
March 27, 2024: Journal of Neurology, Neurosurgery, and Psychiatry